Health ❯ Healthcare ❯ Pharmaceuticals

Weight Loss Drugs

GLP-1 Medications Zepbound Wegovy GLP-1 Receptor Agonists GLP-1 Agonists Mounjaro Ozempic Tirzepatide GLP-1 Drugs Semaglutide Ozempic and Wegovy Eli Lilly Novo Nordisk Clinical Trials Eli Lilly and Novo Nordisk CagriSema GLP-1 Therapies Obesity Treatment Compounded Medications Medicare and Medicaid Coverage GLP-1 Market Competition GLP-1 Injections Bimagrumab Pricing and Accessibility Hims & Hers Health, Inc. Retatrutid Wegovy and Mounjaro GLP-1 Receptor Analogs Ozempic 2.0 Compounded Semaglutide Eli Lilly Zepbound Long-term Effects Patient Management Drug Pricing Advertising in Healthcare Novo Nordisk Wegovy Side Effects Eli Lilly vs Novo Nordisk Incretin Mimetics Market Trends GLP-1 Class Medi-Cal Coverage GLP-1 Treatments Mounjaro and Zepbound GLP-1s Demand and Supply Issues Oral Medications Telehealth GLP-1 Compounds Mounjaro (Tirzepatide) Wegovy and Ozempic Costco Discounts Retatrutide Eli Lilly's Orforglipron Zepbound vs Wegovy Foundayo Wegovy HD Obesity Treatments FDA Approval Ozempic and Mounjaro Orforglipron Market Dynamics Prescription Pricing Ozempic and Tirzepatide Merck & Co., Inc. Eye Health

Mounjaro Study Finds Lower Heart‑Attack Risk as UK Safety Reports Rise

Officials say Yellow Card reports do not prove drugs caused harm.

Study Finds Common GLP‑1 Use and Misuse Among People With Eating Disorders

Penn Study Finds About 30% Lower Breast Cancer Rates Associated With GLP‑1 Use

Cigna Drops GLP-1 Weight-Loss Coverage for Its Employees

CVS Caremark Restores Zepbound and Adds Lilly’s Foundayo to Standard Formularies

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

India Tightens Oversight of GLP-1 Drugs as Semaglutide Generics Proliferate

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

Novo Nordisk to Cut U.S. List Prices for Wegovy, Ozempic and Rybelsus to $675 in 2027

Hims & Hers Shares Fall After Mixed Q4 and Soft Q1 Outlook as GLP‑1 Scrutiny Intensifies

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

CagriSema Beats Semaglutide on HbA1c and Weight at 68 Weeks in Type 2 Diabetes Trial

FDA Approves Novo Nordisk’s Wegovy Pill, First Oral GLP-1

GLP-1 Boom Hits a Crossroads as States Cut Coverage and Next‑Gen Drugs Advance

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

Eli Lilly Lifts 2025 Guidance After Tirzepatide Fuels Blowout Quarter

Lilly Taps Walmart for First Retail Pickup of Discounted Zepbound Vials Starting Mid-November

Costco to Offer Ozempic and Wegovy for $499 a Month to Self-Pay Members Nationwide